BridgeBio Pharma (BBIO) Common Equity (2017 - 2026)

BridgeBio Pharma has disclosed Common Equity across 10 years of filings, most recently posting -$2.3 billion for Q1 2026.

• Common Equity for Q1 2026 came in at -$2.3 billion, down 38.42% year-over-year; the trailing twelve-month figure through Mar 2026 was -$2.3 billion (down 38.42% YoY), and the FY2025 annual result was -$2.1 billion, down 43.14% from the prior year.
• Common Equity came in at -$2.3 billion for Q1 2026 at BridgeBio Pharma, down from -$2.1 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of -$1.0 billion in Q2 2022 to a low of -$2.3 billion in Q1 2026.
• The 5-year median for Common Equity is -$1.2 billion (2022), against an average of -$1.4 billion.
• Across the five-year window, Common Equity tumbled 167.36% in 2022 and gained 19.86% in 2024, its largest moves.
• BridgeBio Pharma's Common Equity stood at -$1.2 billion in 2022, then declined by 8.02% to -$1.3 billion in 2023, then fell by 8.54% to -$1.5 billion in 2024, then sank by 43.14% to -$2.1 billion in 2025, then dropped by 8.69% to -$2.3 billion in 2026.
• The last three Common Equity figures came in at -$2.3 billion (Q1 2026), -$2.1 billion (Q4 2025), and -$1.9 billion (Q3 2025), per Business Quant data.